Aiming,
I don't see it happening that way, but I'm not certain. I still think that CX717 and CX701 will get packaged together, if a deal ever happens. I keep thinking that 1763 or 1739 will be kept in house for all indications. The wildcard in all of this is Schering. If Schering wants rights of first refusal on other, perhaps more potent, Ampakines than it has in its pipeline, then I have no idea how such a deal would be structured, unless Schering wants to get into AD, ADHD, RD, etc. I mean what if Schering thinks that CX701 might be a better molecule than it now has in clinicals for schizophrenia and depression, but it really doesn't want to take CX701 into anything other than schizo and depression? What happens to the other potential indications for CX701?
Is there a theoretical basis--maybe based on binding sites or something like that--that indicates that certain Ampakines would be better suited for certain CNS conditions than others? Or is it all trial and error?
Bladerunner
Market Data 
Markets 
AI
